Kronos Bio Amends Protocol For Its Trial Of KB-0742; Says 'Moving forward, the Company is pursuing a four-days-on, three-days-off dosing schedule to further increase patient time on KB-0742 at or above a therapeutic threshold'
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio has announced an amendment to the protocol for its trial of KB-0742, transitioning to a four-days-on, three-days-off dosing schedule. This change aims to enhance patient time on KB-0742 at or above a therapeutic threshold.
March 05, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio's protocol amendment for KB-0742 trial to a more patient-friendly dosing schedule could positively influence the trial outcomes and investor sentiment.
The amendment to the dosing schedule of KB-0742 by Kronos Bio is likely to be viewed positively by investors as it suggests a strategic approach to enhancing the drug's efficacy and patient adherence. This could lead to more favorable trial outcomes, potentially boosting investor confidence and the stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90